[EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
申请人:DESIGN THERAPEUTICS INC
公开号:WO2021158707A1
公开(公告)日:2021-08-12
The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate
申请人:R.P. Scherer Technologies, LLC
公开号:US20170266302A1
公开(公告)日:2017-09-21
The present disclosure provides conjugate structures and hydrazinyl-substituted heteroaryl compounds used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates and compounds, as well as methods of using the same.
[EN] HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE<br/>[FR] COMPOSÉS HYDRAZINYL-PYRROLO ET PROCÉDÉS DE PRODUCTION D'UN CONJUGUÉ
申请人:REDWOOD BIOSCIENCE INC
公开号:WO2015081282A1
公开(公告)日:2015-06-04
The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. Aspects of the present disclosure include a pharmaceutical composition. The pharmaceutical composition includes a conjugate as described herein and a pharmaceutically acceptable excipient. Aspects of the present disclosure include a method of delivering a conjugate to a subject. The method includes administering to the subject an effective amount of a conjugate as described herein. Aspects of the present disclosure include a method of treating a condition in a subject.
[EN] CELL-PENETRATING, GUANIDINIUM-RICH OLIGOPHOSPHOTRIESTERS FOR DRUG AND PROBE DELIVERY<br/>[FR] OLIGOPHOSPHOTRIESTERS RICHES EN GUANIDINIUM À PÉNÉTRATION CELLULAIRE POUR L'ADMINISTRATION DE MÉDICAMENT ET DE SONDE
申请人:UNIV LELAND STANFORD JUNIOR
公开号:WO2017083637A1
公开(公告)日:2017-05-18
Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.
[EN] CELLS LABELLED WITH LIPID CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CELLULES MARQUÉES PAR DES CONJUGUÉS LIPIDIQUES ET MÉTHODES D'UTILISATION DE CES DERNIÈRES
申请人:UNIV CALIFORNIA
公开号:WO2017079419A1
公开(公告)日:2017-05-11
A method of labelling a cell is provided. Aspects of the method include the contacting the cell with a cholesteryl-cargo conjugate having the formula: C-L-Z (I) wherein C is a cholesterylamine anchor group, L is an optional linker and Z is a linked cargo moiety to non-covalently bind the cholesterylamine anchoring group to the cell membrane thereby displaying Z at the cell surface for an extended period of time. Aspects of the method further include administering the labelled cell to a subject. Also provided is a method of modulating an immune response in a subject and a method of targeting a cell in a subject. Cholesterylamine conjugates, labelled cells and kits including the same that find use in the subject methods are also provided.